Publications

Search or filter publications

Search publications Search

Filter by type:

Filter by publication type

• Book
• Book chapter
• Conference paper
• Journal article
• Patent
• Report
• Software

Filter by year:

Filter from 20252024202320222021202020192018201720162015201420132012201120102009200820072006 to Filter to 20252024202320222021202020192018201720162015201420132012201120102009200820072006

---

Search results

• Conference paper
  Allegretti JR, Kelly C, Grinspan AM, Mullish BH, Hurtado J, Nemes S, Sagi S, Bohm M, Kassam Z, Fischer Met al., 2020,

  S0650 Fecal Microbiota Transplantation Decolonizes C. difficile in Patients With Inflammatory Bowel Disease and Concomitant C. difficile Infection

  , Publisher: Ovid Technologies (Wolters Kluwer Health), Pages: S326-S326, ISSN: 0002-9270
  • Publisher Web Link
  • Cite
• Journal article
  Ianiro G, Segal JP, Mullish BH, Quraishi MN, Porcari S, Fabiani G, Gasbarrini A, Cammarota Get al., 2020,

  Fecal microbiota transplantation in gastrointestinal and extraintestinal disorders

  , Future Microbiology, ISSN: 1746-0913
  • Cite
• Journal article
  Segal JP, Mullish BH, Quraishi MN, Iqbal T, Marchesi JR, Sokol Het al., 2020,

  Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease

  , Therapeutic Advances in Gastroenterology, Vol: 13, Pages: 1-14, ISSN: 1756-2848

  Faecal Microbiota transplantation is currently a recommended therapy for recurrent/refractory Clostridioides difficile infection. The success of FMT for CDI has led to interest in its therapeutic potential in many other disorders. The mechanisms that underpin the efficacy of FMT are not fully understood. Importantly, FMT remains a crucial treatment in managing CDI and hence understanding the mechanisms that underpin its success will be critical to improve its clinical efficacy, safety and usability. Furthermore, a deeper understanding may allow us to expose FMT’s full potential as a therapeutic tool for other disease states. This review will explore the current understanding of the mechanisms underlying the efficacy of FMT across a variety of diseases.

  • Abstract
  • Publisher Web Link
  • Cite
• Journal article
  Ianiro G, Mullish BH, Kelly CR, Kassam Z, Kuijper EJ, Ng SC, Iqbal TH, Allegretti JR, Bibbò S, Sokol H, Zhang F, Fischer M, Costello SP, Keller JJ, Masucci L, van Prehn J, Quaranta G, Quraishi MN, Segal J, Kao D, Satokari R, Sanguinetti M, Tilg H, Gasbarrini A, Cammarota Get al., 2020,

  Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic

  , Gut, Vol: 69, Pages: 1555-1563, ISSN: 0017-5749

  <jats:p>The COVID-19 pandemic has led to an exponential increase in SARS-CoV-2 infections and associated deaths, and represents a significant challenge to healthcare professionals and facilities. Individual countries have taken several prevention and containment actions to control the spread of infection, including measures to guarantee safety of both healthcare professionals and patients who are at increased risk of infection from COVID-19. Faecal microbiota transplantation (FMT) has a well-established role in the treatment of<jats:italic>Clostridioides difficile</jats:italic>infection. In the time of the pandemic, FMT centres and stool banks are required to adopt a workflow that continues to ensure reliable patient access to FMT while maintaining safety and quality of procedures. In this position paper, based on the best available evidence, worldwide FMT experts provide guidance on issues relating to the impact of COVID-19 on FMT, including patient selection, donor recruitment and selection, stool manufacturing, FMT procedures, patient follow-up and research activities.</jats:p>

  • Abstract
  • Publisher Web Link
  • Cite
• Journal article
  Segal JP, Mullish BH, Quraishi MN, Iqbal THet al., 2020,

  Letter: faecal microbiota transplantation for IBS

  , Alimentary Pharmacology &amp; Therapeutics, Vol: 52, Pages: 556-557, ISSN: 0269-2813

  <jats:p><jats:bold>LINKED CONTENT</jats:bold></jats:p><jats:p>This article is linked to Lahtinen et al papers. To view these articles, visit<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1111/apt.15810">https://doi.org/10.1111/apt.15810</jats:ext-link> and <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1111/apt.15875">https://doi.org/10.1111/apt.15875</jats:ext-link>.</jats:p>

  • Abstract
  • Publisher Web Link
  • Cite
• Journal article
  McIlroy JR, Mullish BH, Goldenberg SD, Ianiro G, Marchesi JRet al., 2020,

  Intestinal microbiome transfer, a novel therapeutic strategy for COVID-19 induced hyperinflammation?

  , Clinical Immunology, ISSN: 1521-6616
  • Cite
• Journal article
  Vieira-Silva S, Falony G, Belda E, Nielsen T, Aron-Wisnewsky J, Chakaroun R, Forslund SK, Assmann K, Valles-Colomer M, Nguyen TTD, Proost S, Prifti E, Tremaroli V, Pons N, Le Chatelier E, Andreelli F, Bastard J-P, Coelho LP, Galleron N, Hansen TH, Hulot J-S, Lewinter C, Pedersen HK, Quinquis B, Rouault C, Roume H, Salem J-E, Sondertoft NB, Touch S, Dumas M-E, Ehrlich SD, Galan P, Gotze JP, Hansen T, Holst JJ, Kober L, Letunic I, Nielsen J, Oppert J-M, Stumvoll M, Vestergaard H, Zucker J-D, Bork P, Pedersen O, Backhed F, Clement K, Raes Jet al., 2020,

  Statin therapy is associated with lower prevalence of gut microbiota dysbiosis

  , NATURE, Vol: 581, Pages: 310-+, ISSN: 0028-0836
  • Cite
  • Citations: 201
• Journal article
  Ianiro G, Mullish BH, Kelly CR, Sokol H, Kassam Z, Ng SC, Fischer M, Allegretti JR, Masucci L, Zhang F, Keller J, Sanguinetti M, Costello SP, Tilg H, Gasbarrini A, Cammarota Get al., 2020,

  Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel

  , The Lancet Gastroenterology &amp; Hepatology, Vol: 5, Pages: 430-432, ISSN: 2468-1253
  • Publisher Web Link
  • Cite
• Journal article
  Allegretti JR, Hurtado J, Carrellas M, Marcus J, Nemes S, Marchesi J, Mullish BH, McDonald JA, Phelps EL, Sagi S, Bohm M, Geradin Y, Silverstein M, Kelly CR, Kassam Z, Grinspan A, Fischer Met al., 2020,

  121 ULCERATIVE COLITIS PATIENTS ACHEIVE MORE ROBUST ENGRAFTMENT COMPARED TO PATIENTS WITH CROHN'S DISEASE AFTER FECAL MICROBIOTA TRANSPLANTATION FOR THE TREATMENT OF RECURRENT C. DIFFICLE INFECTION

  , Gastroenterology, Vol: 158, Pages: S-22, ISSN: 0016-5085
  • Publisher Web Link
  • Cite
• Conference paper
  Martinez-Gili L, McDonald JA, Liu Z, Kao DH, Allegretti JR, Barker GF, Blanco JM, Holmes E, Thursz MR, Marchesi J, Mullish BHet al., 2020,

  644 identification of novel changes in microbially-derived metabolites after fecal microbiota transplant for recurrent clostridioides difficile infection

  , Publisher: Elsevier BV, Pages: S-138-S-139, ISSN: 0016-5085
  • Publisher Web Link
  • Cite

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.